ClinConnect ClinConnect Logo
Search / Trial NCT05522075

Reducing Blood Pressure in Mid-life Adult Binge Drinkers

Launched by THE UNIVERSITY OF TEXAS AT ARLINGTON · Aug 26, 2022

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Exercise Training High Intensity Interval Training Midlife Adults Middle Aged Microvascular Function Sympathetic Nerve Activity

ClinConnect Summary

This clinical trial is studying how binge drinking affects blood pressure and blood vessel function in middle-aged adults. The study has two parts. In the first part, researchers will compare the blood pressure and nerve activity of binge drinkers to those who don’t drink alcohol or who drink moderately. In the second part, they will see how an 8-week aerobic exercise program might improve blood pressure and blood vessel function in binge drinkers.

To participate, you need to be a man or woman aged 50 to 64 years. You can be someone who doesn’t drink alcohol, drinks moderately, or binge drinks. However, you cannot have certain health issues, like diabetes or heart disease, or be a smoker. If you join, you’ll undergo tests to measure your blood pressure and how your blood vessels work, and if you're part of the second phase, you’ll participate in an exercise program. This study aims to find ways to help improve health outcomes for binge drinkers as they age.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Men and women (50-64 years of age) who do not drink alcohol, who drink at moderate levels, or who binge drink
  • Female subjects will be postmenopausal (i.e., cessation of menses for ≥1 yr).
  • Subjects who can speak and understand English.
  • Exclusion Criteria:
  • a history of diabetes, cardiovascular disease, liver, or renal disease
  • current or history of smoking and illicit drug use
  • blood pressure ≥160/100 mm Hg
  • other known traditional cardiovascular disease risks: obesity (BMI≥35 kg/m2), or hyperlipidemia (total cholesterol\>230 mg/dl and/or LDL cholesterol\>160 mg/dl)
  • active infection (in the past 2 months)
  • a history of seizures, cancer, or inflammatory disease (i.e., gout or rheumatoid)
  • unstable body weight (\>5% change during the past 6 months)
  • regular aerobic exercise training (i.e., they engage in 30 min of structured aerobic exercise at least 3 times per week)
  • current use of hormone replacement therapy (i.e., estrogen, progesterone, and testosterone)

About The University Of Texas At Arlington

The University of Texas at Arlington (UTA) is a leading academic institution dedicated to advancing research and innovation across various fields, including health sciences. With a strong commitment to improving public health and clinical outcomes, UTA actively sponsors clinical trials that aim to explore novel therapeutics, enhance patient care, and address pressing health challenges. The university's interdisciplinary approach fosters collaboration among researchers, healthcare professionals, and community stakeholders, ensuring that trials are conducted with rigor and integrity. UTA's state-of-the-art facilities and access to diverse patient populations enable the effective execution of clinical research, contributing to the advancement of medical knowledge and practices.

Locations

Arlington, Texas, United States

Patients applied

0 patients applied

Trial Officials

Chueh-Lung Hwang, PhD

Principal Investigator

University of Texas at Arlington

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials